Mapping of Two Phenol Sulfotransferase Genes, STP and STM, to 16p: Candidate Genes for Batten Disease

doi:10.1006/bbrc.1994.2691

Biochemical and Biophysical Research Communications

Volume 205, Issue 1, 30 November 1994, Pages 482-489

https://doi.org/10.1006/bbrc.1994.2691 Get rights and content

Abstract

The cytosolic phenol sulphotransferase gene (STP) was mapped to a region of chromosome 16, within the interval defined by human-rodent somatic cell hybrid breakpoints CY160(D) and CY12, which contains FRA16E. YAC and cosmid clones from this 16p interval were screened for the presence of STP. Two non-overlapping cosmid contigs were identified which contain STP-like sequences. Sequencing of these STP-like sequences confirmed that STP is contained within contig 343.1 and maps proximal to FRA16E, and that a related sulphotransferase STM, encoding the catecholamine-sulphating enzyme, is contained within contig 55.4 and maps to the adjacent hybrid interval CY12-CY180A. Thus two phenol sulphotransferase genes (STP and STM) have been finely localised to chromosome 16p12.1-p11.2, to the same region as CLN3, the gene for Batten disease. Both genes are therefore candidate genes for Batten disease.

References (0)

Cited by (41)

Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism
2022, Drug Discovery Today
Citation Excerpt :
The reference in vitro substrate for SULT1A1 is 4-nitrophenol (p-nitrophenol, PNP), which has a higher affinity for SULT1A1/2 than for other human SULT isoforms.29,30 The gene encoding SULT1A1 is on the short arm of chromosome 16.31 The most frequent SULT1A1 polymorphisms identified (Table 1) are SULT1A1*1 (the wild type, WT), SULT1A1*2 containing the AA substitution R213H, and SULT1A1*3 containing the M223V substitution.
Sulfotransferases (SULTs) are Phase II drug-metabolizing enzymes (DMEs) catalyzing the sulfation of a variety of endogenous compounds, natural products, and drugs. Various drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDS) can inhibit SULTs, affecting drug–drug interactions. Several polymorphisms have been identified for SULTs that might be crucial for interindividual variability in drug response and toxicity or for increased disease risk. Here, we review current knowledge on non-synonymous single nucleotide polymorphisms (nsSNPs) of human SULTs, focusing on the coded SULT allozymes and molecular mechanisms explaining their variable activity, which is essential for personalized medicine. We discuss the structural and dynamic bases of key amino acid (AA) variants implicated in the impacts on drug metabolism in the case of SULT1A1, as revealed by molecular modeling approaches.
Sulfotransferases
2018, Comprehensive Toxicology: Third Edition
Sulfotransferases catalyze the formation of sulfuric acid esters, most often referred to as sulfates, from a wide range of xenobiotics and their metabolites, as well as various endogenous neurotransmitters, hormones, bile acids, carbohydrates, and proteins. This article is focused on the cytosolic sulfotransferases, a superfamily of enzymes that, depending on the specific substrates and products of the sulfation reaction, are responsible for either detoxication or metabolic activation of a wide range of drugs, toxins, carcinogens, environmental chemicals, and other xenobiotics. An overview of current aspects of the nomenclature, gene organization, regulation of expression, enzyme structures and catalytic mechanisms, specificities for substrates and inhibitors, and roles in toxicology is provided for these cytosolic sulfotransferases.
Structural plasticity in the human cytosolic sulfotransferase dimer and its role in substrate selectivity and catalysis
2015, Drug Metabolism and Pharmacokinetics
The cytosolic sulfotransferases (SULTs) are dimeric enzymes that help maintain homeostasis through the modulation of hormone and drug activity by catalyzing their transformation into hydrophilic sulfate esters and increasing their excretion. Each of the thirteen active human SULT isoforms displays a unique substrate specificity pattern that underlies its individual role in our bodies. These specificities have proven to be complex, in some cases masking the biological role of specific isoforms. The first part of this review offers a short summary of historical underpinnings of human SULTs, primarily centered on the characterization of each isoform's kinetic and structural properties. Recent structural investigations have revealed each SULT has an active site “lid” that undergoes restructuring once the cofactor/sulfonate donor, 3′-phosphoadenosine-5′-phosphosulfate (PAPS), binds to the enzyme. This structural rearrangement can alter substrate-binding profiles, therefore complicating enzyme/substrate interactions and making substrate/cosubstrate concentrations and binding order important considerations in enzyme functionality. Molecular dynamic simulations have recently been employed to describe this restructuring in an attempt to offer insight to its effects on substrate selectivity. In addition to reviewing new data on SULT molecular dynamics, we will discuss the contribution of PAPS concentrations and SULT dimerization in the regulation of SULT activity within the human body.
Sulfotransferases
2010, Comprehensive Toxicology, Second Edition
Sulfotransferases catalyze the formation of sulfuric acid esters, most often referred to as sulfates, from a wide range of xenobiotics and their metabolites, as well as various endogenous neurotransmitters, hormones, bile acids, carbohydrates, and proteins. This chapter is focused on the cytosolic sulfotransferases, a superfamily of enzymes that, depending on the specific substrates and products of the sulfation reaction, are responsible for either detoxication or metabolic activation of a wide range of drugs, toxins, carcinogens, environmental chemicals, and other xenobiotics. An overview of current aspects of the nomenclature, gene organization, regulation of expression, enzyme structures and catalytic mechanisms, specificities for substrates and inhibitors, and roles in toxicology is provided for these cytosolic sulfotransferases.
Sulfation and glucuronidation of phenols: Implications in coenyzme Q metabolism
2005, Methods in Enzymology
Citation Excerpt :
The SULT1A subfamily responsible for the sulfation of the majority of simple phenols and biogenic amines has been localized on adjacent hybrid intervals on chromosome 16p12.1‐p11.2. This configuration likely arose from gene duplication leading to a divergence in sequence evolution (Dooley et al., 1993, 1994). Further analysis of this loci revealed that polymorphisms do exist in all three subfamily isoforms, which likely play a prominent role in some individual variations in drug metabolism.
Phase II conjugation of phenolic compounds constitutes an important mechanism through which exogenous or endogenous toxins are detoxified and excreted. Species differences in the rates of glucuronidation or sulfation can lead to significant variation in the metabolism of this class of compounds. Conjugation of the hydroxyl groups of phenols can occur with glucuronate or sulfate. Quinone metabolism, deactivation, and detoxification are also affected by the same conjugatory systems as phenols; however, reduction of quinones to hydroquinols seems to be a prerequisite. This work reviews current knowledge on phenol conjugation and its implications on hydroquinone metabolism with special consideration for coenzyme Q metabolism.
Human SULT1A genes: Cloning and activity assays of the SULT1A promoters
2005, Methods in Enzymology
Citation Excerpt :
SULT1A3 is currently positioned in the opposite direction to the other SULT1A genes. The SULT1A3 gene differs mainly in its 5′ promoter sequence and shares about 70% sequence identity with the other two SULT1A genes (Aksoy and Weinshilboum, 1995; Bernier et al., 1994a; Dooley et al., 1994). Structurally the three SULT1A genes are similar.
The three human SULT1A sulfotransferase enzymes are closely related in amino acid sequence (>90%), yet differ in their substrate preference and tissue distribution. SULT1A1 has a broad tissue distribution and metabolizes a range of xenobiotics as well as endogenous substrates such as estrogens and iodothyronines. While the localization of SULT1A2 is poorly understood, it has been shown to metabolize a number of aromatic amines. SULT1A3 is the major catecholamine sulfonating form, which is consistent with it being expressed principally in the gastrointestinal tract. SULT1A proteins are encoded by three separate genes, located in close proximity to each other on chromosome 16. The presence of differential 5′‐untranslated regions identified upon cloning of the SULT1A cDNAs suggested the utilization of differential transcriptional start sites and/or differential splicing. This chapter describes the methods utilized by our laboratory to clone and assay the activity of the promoters flanking these different untranslated regions found on SULT1A genes. These techniques will assist investigators in further elucidating the differential mechanisms that control regulation of the human SULT1A genes. They will also help reveal how different cellular environments and polymorphisms affect the activity of SULT1A gene promoters.

View all citing articles on Scopus

View full text

Regular ArticleMapping of Two Phenol Sulfotransferase Genes, STP and STM, to 16p: Candidate Genes for Batten Disease

Abstract

Regular Article
Mapping of Two Phenol Sulfotransferase Genes, STP and STM, to 16p: Candidate Genes for Batten Disease